Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone415-482-5300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.19 billion
Profitability
Miscellaneous
Employees618
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions
What is Nektar Therapeutics' stock symbol?
Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."
How were Nektar Therapeutics' earnings last quarter?
Nektar Therapeutics (NASDAQ:NKTR) announced its earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.71) by $0.03. The biopharmaceutical company earned $28.22 million during the quarter, compared to analyst estimates of $25.45 million. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. During the same quarter last year, the firm posted ($0.60) earnings per share. View Nektar Therapeutics' Earnings History.
When is Nektar Therapeutics' next earnings date?
What price target have analysts set for NKTR?
10 analysts have issued 1-year price targets for Nektar Therapeutics' stock. Their forecasts range from $38.00 to $100.00. On average, they anticipate Nektar Therapeutics' share price to reach $71.5556 in the next year. This suggests a possible upside of 103.5% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics.
What is the consensus analysts' recommendation for Nektar Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nektar Therapeutics.
What are Wall Street analysts saying about Nektar Therapeutics stock?
Here are some recent quotes from research analysts about Nektar Therapeutics stock:
- 1. William Blair analysts commented, "We traveled with LeMaitre management last week as the company met with Barrington clients in Richmond, VA. This marked the second time in a month that we have spent time on the road with members of this management team and the messaging remains consistent and long-term bullish despite some short-term challenges." (6/14/2019)
- 2. According to Zacks Investment Research, "Nektar reported encouraging first-quarter results, beating estimates for both earnings and sales. The company has a promising pipeline with several candidates and regulatory updates lined up for the next several quarters. Additionally, regular partnerships have enhanced the company’s financial position. Nektar is poised to receive significant sales milestone payments plus royalties for Movantik, Adynovate and Neulasta, under license agreements with AstraZeneca, Takeda and Amgen, respectively. Also, its recent co-development deals with Lilly for NKTR-358 and Bristol-Myers for NKTR-214 are encouraging. The deals provide revenues and reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company’s results in the future. Shares of the company have underperformed the industry so far this year." (5/14/2019)
- 3. HC Wainwright analysts commented, "Our 12-month, $47 price target on shares of Nektar is based on a 13-year DCF-driven, sum-of-the-parts analysis. Our DCF is driven by beta of 1.24, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.0%, and tax rate of 15% beginning in FY 2023. Cancer together represent about 71% of our target. In RCC, we assume commercial adoption in patients with PD-L1 expression at <1% (about 67% of the total clear cell RCC opportunity)."" (3/4/2019)
- 4. Mizuho analysts commented, "We expect these events to be important drivers for NKTR shares as we continue to believe that a majority of the company’s value lies in NKTR-214." (3/1/2019)
Has Nektar Therapeutics been receiving favorable news coverage?
Media coverage about NKTR stock has been trending positive recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nektar Therapeutics earned a news sentiment score of 2.6 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for Nektar Therapeutics.
Who are some of Nektar Therapeutics' key competitors?
Some companies that are related to Nektar Therapeutics include BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Catalent (CTLT), Array Biopharma (ARRY) and GALAPAGOS NV/S (GLPG).
What other stocks do shareholders of Nektar Therapeutics own?
Who are Nektar Therapeutics' key executives?
Nektar Therapeutics' management team includes the folowing people:
- Mr. Howard W. Robin, CEO, Pres & Director (Age 66)
- Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 47)
- Mr. John Nicholson, Sr. VP & COO (Age 67)
- Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. & Chief Technical Operations Officer (Age 65)
- Dr. Stephen K. Doberstein, Chief R&D Officer (Age 60)
Who are Nektar Therapeutics' major shareholders?
Nektar Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (11.72%), Primecap Management Co. CA (11.11%), BlackRock Inc. (7.18%), Janus Henderson Group PLC (1.41%), First Trust Advisors LP (1.23%) and Frontier Capital Management Co. LLC (0.48%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.
Which major investors are selling Nektar Therapeutics stock?
NKTR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., First Trust Advisors LP, Tocqueville Asset Management L.P., Janus Henderson Group PLC, Bank of Montreal Can, Marshall Wace LLP and California Public Employees Retirement System. Company insiders that have sold Nektar Therapeutics company stock in the last year include Dennis L Winger, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Maninder Hora, R Scott Greer and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.
Which major investors are buying Nektar Therapeutics stock?
NKTR stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, SG Americas Securities LLC, Acadian Asset Management LLC, Sumitomo Mitsui Trust Holdings Inc., Empire Life Investments Inc., Nisa Investment Advisors LLC, Frontier Capital Management Co. LLC and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Nektar Therapeutics.
How do I buy shares of Nektar Therapeutics?
Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nektar Therapeutics' stock price today?
One share of NKTR stock can currently be purchased for approximately $35.17.
How big of a company is Nektar Therapeutics?
Nektar Therapeutics has a market capitalization of $6.13 billion and generates $1.19 billion in revenue each year. The biopharmaceutical company earns $681.31 million in net income (profit) each year or $3.78 on an earnings per share basis. Nektar Therapeutics employs 618 workers across the globe.View Additional Information About Nektar Therapeutics.
What is Nektar Therapeutics' official website?
How can I contact Nektar Therapeutics?
Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]
MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
